Cystic fibrosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]

Cystic fibrosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cystic fibrosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiography or Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cystic fibrosis medical therapy On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cystic fibrosis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cystic fibrosis medical therapy
CDC on Cystic fibrosis medical therapy
Cystic fibrosis medical therapy in the news
Blogs on Cystic fibrosis medical therapy
Directions to Hospitals Treating Cystic fibrosis
Risk calculators and risk factors for Cystic fibrosis medical therapy

Medical Therapy

• Inhaled osmotic agent/ Hypertonic saline: Increase the airway fluid layer
• Dornase alfa [recombinant human deoxyribo-nuclease (DNase)]: Cleave the extracellular DNA and aid airway clearance (DNA significantly increases the viscosity of the sputum)

References

Template:WikiDoc Sources